Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Camps

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM groupM Martin, A Villar, A Sole-Calvo, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|October 6, 2010
[Consensus document on the use of granulocyte colony stimulating factor biosimilars for correction of neutropenia in cancer patients]E Aranda Aguilar, C Camps Herrero, A Carrato Mena, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 11, 2018
Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)C Camps Herrero, J J Reina Zoilo, D Monge Martín, et al.
Clinical Lung Cancer|January 22, 2004
Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trialE Felip, R Rosell, V Alberola, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 5, 2017
Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE studyR López López, C Camps Herrero, P Khosravi-Shahi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 14, 2014
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologistsC Camps-Herrero, L Paz-Ares, M Codes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancerD Isla, C Sarries, R Rosell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2006
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patientsR de las Peñas, M Sanchez-Ronco, V Alberola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2005
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trialC Camps, B Massuti, A Jiménez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trialV Alberola, C Camps, M Provencio, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM groupM Martin, A Villar, A Sole-Calvo, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|October 6, 2010
[Consensus document on the use of granulocyte colony stimulating factor biosimilars for correction of neutropenia in cancer patients]E Aranda Aguilar, C Camps Herrero, A Carrato Mena, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 11, 2018
Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)C Camps Herrero, J J Reina Zoilo, D Monge Martín, et al.
Clinical Lung Cancer|January 22, 2004
Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trialE Felip, R Rosell, V Alberola, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 5, 2017
Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE studyR López López, C Camps Herrero, P Khosravi-Shahi, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 14, 2014
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologistsC Camps-Herrero, L Paz-Ares, M Codes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2004
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancerD Isla, C Sarries, R Rosell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2006
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patientsR de las Peñas, M Sanchez-Ronco, V Alberola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2005
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trialC Camps, B Massuti, A Jiménez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trialV Alberola, C Camps, M Provencio, et al.
Pageof 11